ReviewFrontiers in cellular and infection microbiology2022
Innate and adaptive immune evasion by dengue virus.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- HLA alleles and dengue susceptibility across populations in the era of climate change: a comprehensive review.Frontiers in immunology · 2025Pooled it
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
- Global, Regional, and National Burden of Malaria and Dengue from 1992 to 2021, with Projections to 2036: An Age-Period-Cohort Analysis.Tropical medicine and infectious disease · 2026Article
- The Role of Natural Killer (NK) Cells in Dengue Virus Infection: A Narrative Review.Health science reports · 2026Article
- Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- Article
- Host serum-circulating flavivirus NS1 co-opts mosquito miRNA processing to suppress early immune defense.Nature communications · 2026Article
- Dengue Fever and Its Burden in Burkina Faso: An Overview.Reviews in medical virology · 2026Review
- Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program.Frontiers in immunology · 2026Review
- Contribution of Immune Responses toJournal of inflammation research · 2026Article
- Designing a multi-epitope vaccine against dengue virus-2 usingBioImpacts : BI · 2026Article
- Transcriptomic and bioinformatics analysis reveals the host response feature and potential treatment strategy of patients with dengue fever.Frontiers in immunology · 2026Article
- The bittersweet link between glucose metabolism, cellular microenvironment and viral infection.Virulence · 2025Review
- Dengue Virus and the Host Immune System: A Battle of Immune Modulation, Response and Evasion.Pathogens (Basel, Switzerland) · 2025Review
- Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance.EMBO molecular medicine · 2025Article
- Histopathological Alterations and Dysregulation of Type I Interferon Signaling in the Human Cerebral Cortex During Severe Dengue.Journal of medical virology · 2025Article
- Article
- The Impacts of Dengue Virus Infection on Mitochondrial Functions and Dynamics.International journal of molecular sciences · 2025Review
- Integrative Mechanistic Studies Identify Reticulon-3 as a Critical Modulator of Infectious Exosome-Driven Dengue Pathogenesis.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a mosquito-borne disease which causes significant public health concerns in tropical and subtropical countries. Dengue virus (DENV) has evolved various strategies to manipulate the innate immune responses of the host such as 'hiding' in the ultrastructure of the host, interfering with the signaling pathway through RNA modifications, inhibiting type 1 IFN production, as well as inhibiting STAT1 phosphorylation. DENV is also able to evade the adaptive immune responses of the host through antigenic variation, antigen-dependent enhancement (ADE), partial maturation of prM proteins, and inhibition of antigen presentation. miRNAs are important regulators of both innate and adaptive immunity and they have been shown to play important roles in DENV replication and pathogenesis. This makes them suitable candidates for the development of anti-dengue therapeutics. This review discusses the various strategies employed by DENV to evade innate and adaptive immunity. The role of miRNAs and DENV non-structural proteins (NS) are promising targets for the development of anti-dengue therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.